ClinicalTrials.gg
Not yet recruitingNCT07608458Updated Nov 10, 2026

Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy

An interventional study of Actigraphy and Online Mindfulness Meditation in Hepatocellular Carcinoma, Pancreas Cancer and Biliary Tract Neoplasms, sponsored by City of Hope Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 10, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Carcinoma, Hepatocellular by City of Hope Medical Center — 4 open to participants now, 8 under way, none of them phase 3. Carcinoma, Hepatocellular · City of Hope Medical Center.

Started
2027
the only one that year
No phase
4 of 14
1 open now
Registered
14th of 14
by date

Among the 14 studies in Carcinoma, Hepatocellular by City of Hope Medical Center, this one is the only one that started in 2027, is one of 4 with no phase, and was the 14th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

4 of the 14 studies in Carcinoma, Hepatocellular by City of Hope Medical Center are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Carcinoma, Hepatocellular by City of Hope Medical Center, or all of them as a file.
02

Study summary

This clinical trial tests the feasibility and how well a scheduled meditation intervention works to improve postoperative outcomes such as pain, anxiety, insomnia, stress and mobility for patients undergoing pancreatectomy. Many patients undergoing pancreatectomy surgery report clinically important fatigue, pain, and/or reduction in quality of life. Meditation is a behavioral intervention that has been studied in a variety of medical and surgical settings, where it has been associated with reductions in pain, anxiety, blood pressure, and lack of sleep, and in some cases with decreased pain and shorter length of stay. The meditation intervention using Headspace is an easily accessible and interactive way to complete scheduled meditation. This may improve postoperative outcomes for patients undergoing pancreatectomy.

Read the detailed description

PRIMARY OBJECTIVES:

I. Evaluate the feasibility of implementing a meditation-based intervention in patients undergoing pancreatectomy, as measured by recruitment, retention, and participant compliance with the prescribed modules II. Evaluate the effect of a perioperative meditation intervention on anxiety, as measured by changes in State-Trait Anxiety Inventory (STAI) scores from baseline to one month postoperatively.

SECONDARY OBJECTIVE:

I. To observe the relationship of meditation intervention on change in health-related quality of life (HRQOL) outcomes for pain and sleep quality from baseline through one month postoperatively.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive access to the Headspace application. Patients complete mindfulness meditation including focused breathing, awareness of thought patterns, and management of mind-wandering for 10 minutes once daily (QD) for 3 weeks prior to surgery and twice daily (BID) for 1 month after surgery. Patients wear a Garmin activity tracker throughout the study.

ARM II: Patients receive access to the Headspace application at the time of hospital discharge and will be informed of the availability of the "Basics" meditation pack. Patients wear a Garmin activity tracker throughout the study.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Pancreas Cancer
  • Biliary Tract Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative
  • Willing to install required apps on personal smartphone
  • Willing to wear a Garmin wearable device throughout the study
  • Age: ≥ 18 years
  • Ability to read and understand English for questionnaires
  • Owns a smartphone
  • Comfortable with routine smartphone use
  • Scheduled to undergo pancreatectomy

Exclusion criteria

Exclusion Criteria:

  • Participants with prior formal training in meditation or mindfulness (e.g., completion of structured courses, workshops, or certification programs)
  • Participants who currently engage in a structured meditation or mindfulness practice, including regular use of mobile applications (e.g., Headspace, Calm, or similar platforms) or other formalized routines
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Arm I (Headspace meditation)

    Patients receive access to the Headspace application. Patients complete mindfulness meditation including focused breathing, awareness of thought patterns, and management of mind-wandering, for 10 minutes QD for 3 weeks prior to surgery and BID for 1 month after surgery. Patients wear a Garmin activity tracker throughout the study.

    Other: Actigraphy · Behavioral: Online Mindfulness Meditation · Behavioral: Smartphone Application-based Intervention · Other: Survey Administration

  • Experimental
    Arm II (Delayed access to Headspace)

    Patients receive access to the Headspace application at the time of hospital discharge and will be informed of the availability of the "Basics" meditation pack. Patients wear a Garmin activity tracker throughout the study.

    Other: Actigraphy · Behavioral: Online Mindfulness Meditation · Behavioral: Smartphone Application-based Intervention · Other: Survey Administration

Interventions

  • OtherActigraphy

    Wear activity tracker

  • BehavioralOnline Mindfulness Meditation

    Complete mindfulness mediation

    Also known as: Online MBSR, Online Mindful Meditation, Online Mindfulness Relaxation, Online Mindfulness-Based Stress Reduction, Web-Based Mindfulness Meditation

  • BehavioralSmartphone Application-based Intervention

    Receive access to Headspace

    Also known as: Smartphone App-based Intervention, Smartphone Intervention, Smartphone-based Intervention

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Proportion of enrolled patients who complete the final study assessment (retention)

    Retention will be considered feasible if ≥ 70% of enrolled participants are retained. Will be estimated along with the 95% exact binomial confidence interval.

    Time frame: Up to 6 months

  2. Proportion of prescribed meditation modules completed (compliance)

    Each participant's proportion of completed meditation modules will be calculated using usage data from the Headspace mobile application. Participants will then be classified as high (\> 60%), medium (20-60%), or low (\< 20%) compliance. Will be estimated along with the 95% exact binomial confidence interval.

    Time frame: Up to 6 months

  3. Change in patient-reported anxiety symptoms

    Measured using the State-Trait Anxiety Inventory (STAI). Response is defined as a reduction of at least 6 points on STAI at date of surgery date relative to baseline. The proportion of participants meeting this threshold will be reported. Will be estimated along with the 95% exact binomial confidence interval. Within-group mean change in STAI will be examined using paired t-tests (comparing any two time points of interest).

    Time frame: From baseline up to day 28

  4. Proportion of invited patients who agree to participate (recruitment)

    Recruitment will be considered feasible if ≥ 50% of eligible patients enroll. Will be estimated along with the 95% exact binomial confidence interval.

    Time frame: Up to 6 months

Secondary outcomes

  1. Change in patient-reported pain - Numeric Rating Scale

    Change in patient-reported pain from baseline three weeks prior to surgery through one month postoperatively, measured using the Numeric Rating Scale (NRS, 0 -10 ). 0 means no pain to 10 means worst pain possible.

    Time frame: rom the baseline assessment conducted three weeks prior to surgery through one month after surgery.

  2. Change in patient-reported pain - Brief Pain Inventory

    Change in patient-reported pain from baseline three weeks prior to surgery through one month postoperatively, measured using the Brief Pain Inventory.(BPI). 0 means no pain to 10 means worst pain possible.

    Time frame: From the baseline assessment conducted three weeks prior to surgery up to one month after surgery.

  3. Change in patient-reported Pittsburgh Sleep Quality Index (PSQI)

    Self-reported questionnaire will be used to measure sleep quality and sleep patterns over the past month. PSQI will be interpreted by totaling the component scores into a global score ranging from 0 to 21, where higher scores indicate poorer sleep quality; a score greater than 5 generally suggests significant sleep disturbance or poor sleep quality.

    Time frame: From baseline up to one month after surgery.

  4. Change in patient-reported Insomnia Severity Index (ISI)

    Self-reported questionnaire will be used to assess the severity and impact of insomnia symptoms, including difficulty falling asleep, staying asleep, and the effect of sleep problems on daily functioning. The ISI is interpreted using a total score from 0 to 28: 0-7 indicates no clinically significant insomnia, 8-14 indicates subthreshold insomnia, 15-21 indicates moderate insomnia, and 22-28 indicates severe insomnia.

    Time frame: From baseline up to one month after surgery.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Nov 2027, 10 months later.

Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 10 months is below that.

Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Oct 2026 → Jan 2027, primary completion Nov 2026 → Nov 2027 and completion Nov 2026 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
May 27, 2026
StartEst.
Jan 1, 2027was Oct 2026
Primary completionEst.
Nov 25, 2027was Nov 2026
CompletionEst.
Nov 25, 2027was Nov 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Jan 1, 2027
Nov 10, 2026
Primary completion
Nov 25, 2026→Nov 25, 2027
Nov 10, 2026
Study completion
Nov 25, 2026→Nov 25, 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Start date Oct 1, 2026→Jan 1, 2027
    Primary completion Nov 25, 2026→Nov 25, 2027
    Study completion Nov 25, 2026→Nov 25, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07608458
Responsible party
Sponsor
First posted
May 27, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Nov 25, 2027 (estimated)
Completion
Nov 25, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Bradford Kim
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion